Tenet Healthcare : Q3 2025 Financial Results Webcast Press Release

Tenet Reports Strong Third Quarter 2025 Results; Raises 2025 Financial Outlook

• Net income available to common shareholders in third quarter 2025 was $342 million, or $3.86 per diluted share
• Adjusted diluted earnings per share1 increased 26.3% to $3.70 in third quarter 2025 compared to $2.93 in third quarter 2024
• Consolidated Adjusted EBITDA1 in third quarter 2025 increased 12.4% to $1.099 billion compared to third quarter 2024; Third quarter 2025 Adjusted EBITDA margin was 20.8%
• Third quarter 2025 Ambulatory Care Adjusted EBITDA of $492 million increased 12.1% over third quarter 2024
• FY 2025 Adjusted EBITDA Outlook is now expected to be in the range of $4.47 billion to $4.57 billion, a $50 million increase at the midpoint

DALLAS - October 28, 2025 - Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended September 30, 2025.

"Our high acuity service line focus and operational discipline enabled us to deliver strong same store revenue growth and attractive operational performance and free cash flow in the third quarter," said Saum Sutaria, M.D., Chairman and Chief Executive Officer of Tenet. "We are well positioned for continued growth as we execute on our strategy in each of our markets."

Tenet's results for third quarter 2025 versus third quarter 2024 are as follows:

Three Months Ended September 30, Nine Months Ended September 30,

($ in millions, except per share results)	2025	2024	2025	2024
Net operating revenues	$5,289	$5,126	$15,783	$15,602
Net income available to Tenet common shareholders	$342	$472	$1,036	$2,882
Net income available to Tenet common shareholders per
diluted share	$3.86	$4.89	$11.28	$29.27
Adjusted EBITDA1	$1,099	$978	$3,383	$2,947
Adjusted diluted earnings per share1	$3.70	$2.93	$12.10	$8.47

• Net income available to the Company's common shareholders in third quarter 2025 was

  $342 million, or $3.86 per diluted share, versus $472 million, or $4.89 per diluted share, in third quarter 2024. Third quarter 2024 results included a pre-tax gain of $348 million ($209 million after-tax or $2.16 per diluted share) primarily associated with the sale of the Company's 70% majority ownership interest in Brookwood Baptist Health in Alabama.

• Adjusted EBITDA1 in third quarter 2025 was $1.099 billion compared to $978 million in third quarter 2024, reflecting strong growth in same facility revenue, higher acuity, favorable payer mix, and disciplined expense management.

• In the third quarter of 2025, the Hospital segment recognized a $38 million favorable pre-tax impact associated with additional Medicaid supplemental revenues related to prior years.

  Balance Sheet and Cash Flows

• Cash flows provided by operating activities for the nine months ended September 30, 2025 were $2.809 billion versus $2.378 billion for the nine months ended September 30, 2024.

• The Company produced free cash flow1 of $2.163 billion for the nine months ended September 30, 2025 versus $1.777 billion for the nine months ended September 30, 2024.

• In the three months ended September 30, 2025, the Company repurchased 0.6 million shares of common stock for $93 million. In the nine months ended September 30, 2025, the Company repurchased 7.8 million shares of common stock for $1.188 billion.

• The Company's ratio of net debt to Adjusted EBITDA1 was 2.30x at September 30, 2025 compared to 2.45x at June 30, 2025 and 2.54x at December 31, 2024.

  Ambulatory Care (Ambulatory) Segment

  Tenet's Ambulatory business segment is comprised of the operations of United Surgical Partners International (USPI). As of September 30, 2025, USPI had interests in 530 ambulatory surgery centers (398 consolidated) and 26 surgical hospitals (eight consolidated) in 37 states.

  Three Months Ended September 30, Nine Months Ended September 30,

  Ambulatory segment results ($ in millions)	2025	2024	2025	2024
  Revenues
  Net operating revenues	$1,275	$1,139	$3,739	$3,275
  Same-facility system-wide net patient service revenues2	$2,109	$1,947	$6,109	$5,682
  Changes versus the Prior-Year Period
  Same-facility system-wide net patient service revenues	8.3 %	8.7 %	7.5 %	7.5 %
  Same-facility system-wide net patient service revenue
  per case	6.1 %	7.6 %	7.7 %	7.0 %
  Same-facility system-wide surgical cases2	2.1 %	1.0 %	(0.2)%	0.4 %
  Same-facility system-wide surgical cases on same-
  business day basis2	2.1 %	(0.6)%	0.4 %	(0.1)%
  Adjusted EBITDA, Margins and NCI
  Adjusted EBITDA	$492	$439	$1,446	$1,280
  Adjusted EBITDA margin	38.6%	38.5%	38.7%	39.1%
  Adjusted EBITDA less NCI	$292	$265	$874	$779

• Third quarter 2025 net operating revenues increased 11.9% compared to third quarter 2024 driven by strong growth in same-facility net patient services revenues, acquisitions of facilities, and increased service lines.

• Surgical business same-facility system-wide net patient service revenues increased 8.3% in third quarter 2025 compared to third quarter 2024, with cases up 2.1% and net revenue per case up 6.1%. Net revenue per case growth was driven by favorable case mix, increases in higher acuity volumes over the prior year, as well as favorable payer mix.

• Third quarter 2025 Adjusted EBITDA increased 12.1% compared to third quarter 2024, due to strong growth in same-facility net patient service revenues, disciplined expense management, and contributions from acquisitions.

  Hospital Operations and Services (Hospital) Segment

  Tenet's Hospital business segment is primarily comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro-hospitals and physician practices. It also provides comprehensive end-to-end and focused point services, including hospital and physician revenue cycle management, patient communications and engagement support and value-based care solutions.

  Three Months Ended September 30, Nine Months Ended September 30,

  Hospital segment results ($ in millions)	2025	2024	2025	2024
  Revenues
  Net operating revenues	$4,014	$3,987	$12,044	$12,327
  Same-hospital net patient service revenues3 Same-Hospital Volume Changes versus the Prior-Year Period	$3,422	$3,184	$10,296	$9,688
  Admissions	1.5%	5.2%	2.5%	4.9%
  Adjusted admissions4	1.4%	2.7%	1.6%	2.3%
  Outpatient visits (including outpatient ER visits)	(1.5)%	0.5%	(1.4)%	0.1%
  Emergency Room visits (inpatient and outpatient)	(2.0)%	(0.2)%	(1.8)%	1.8%
  Hospital surgeries Adjusted EBITDA	0.7%	0.6%	(0.8)%	-%
  Adjusted EBITDA	$607	$539	$1,937	$1,667
  Adjusted EBITDA margin	15.1%	13.5%	16.1%	13.5%

• Third quarter 2025 net operating revenues increased 0.7% from third quarter 2024 primarily due to growth in same hospital adjusted admissions, favorable payer mix and higher acuity, partially offset by the impact of hospital divestitures in 2024.

• Same-hospital net patient service revenue per adjusted admission increased 5.9% year-over-year for third quarter 2025 primarily due to favorable payer mix, increased Medicaid supplemental revenues, and our focus on growing higher acuity services.

• Adjusted EBITDA in third quarter 2025 was $607 million compared to $539 million in third quarter 2024, reflecting strong same-hospital revenue growth, favorable payer mix, and disciplined expense management.

• In the third quarter of 2025, the Hospital segment recognized a $38 million favorable pre-tax impact associated with additional Medicaid supplemental revenues related to prior years.

2025 Outlook1

Tenet's Outlook for full year 2025 (consolidated and by segment) follows.

CONSOLIDATED ($ in millions, except per share amounts)	FY 2025 Outlook
Net operating revenues	$21,150 to $21,350
Net income available to Tenet common stockholders	$1,334 to $1,399
Adjusted EBITDA	$4,470 to $4,570
Adjusted EBITDA margin	21.1% to 21.4%
Diluted income per common share	$14.66 to $15.37
Adjusted net income	$1,450 to $1,480
Adjusted diluted earnings per share	$15.93 to $16.26
Equity in earnings of unconsolidated affiliates	$255 to $265
Depreciation and amortization	$820 to $850
Interest expense	$815 to $825
Income tax expense5	$510 to $535
Net income available to NCI	$940 to $990
Weighted average diluted common shares	~91 million
Net cash provided by operating activities	$3,150 to $3,500
Adjusted net cash provided by operating activities	$3,300 to $3,600
Capital expenditures	$875 to $975
Free cash flow	$2,275 to $2,525
Adjusted free cash flow	$2,425 to $2,625
NCI cash distributions	$780 to $830

Ambulatory Segment ($ in millions)	FY 2025 Outlook
Net operating revenues	$5,100 to $5,150
Adjusted EBITDA	$2,000 to $2,040
NCI	$790 to $820
Adjusted EBITDA less NCI	$1,210 to $1,220
Changes versus prior year6:
Same-facility system-wide revenue	Up 5.5% to 7.5%

Hospital Segment ($ in millions)	FY 2025 Outlook
Net operating revenues	$16,050 to $16,200
Adjusted EBITDA	$2,470 to $2,530
NCI	$150 to $170
Changes versus prior year6:
Inpatient admissions	Up 2.0% to 3.0%
Adjusted admissions	Up 1.5% to 2.5%

Management's Webcast Discussion of Results

Tenet management will discuss the Company's third quarter 2025 results in a webcast scheduled for 10:30 a.m. Eastern Time (9:30 a.m. Central Time) on October 28, 2025. Investors can access the webcast through the Company's website at https://www.tenethealth.com/investors.

The slide presentation associated with the webcast referenced above, a copy of this earnings press release, and a related supplemental financial disclosures document will be available on the Company's Investor Relations website on October 28, 2025.

Cautionary Statement

This release contains "forward-looking statements" - that is, statements that relate to future, not past, events. In this context, forward-looking statements often address the Company's expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "assume," "believe," "budget," "estimate," "forecast," "intend," "plan," "predict," "project," "seek," "see," "target," or "will." Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Particular uncertainties that could cause the Company's actual results to be materially different than those expressed in the Company's forward-looking statements include, but are not limited to the factors disclosed under "Forward-Looking Statements" and "Risk Factors" in our Form 10-K for the year ended December 31, 2024 and other filings with the Securities and Exchange Commission.

Footnotes

1. Tables and discussions throughout this earnings release include certain financial measures, including those related to our full year 2025 Outlook, that are not in accordance with accounting principles generally accepted in the United States of America (GAAP). Reconciliations of GAAP measures to the Adjusted (non-GAAP) measures used are detailed in Tables #1-6 included at the end of this earnings release. Management's reasoning for the use of these

   non-GAAP measures and descriptions of the various non-GAAP measures are included in the Non-GAAP Financial Measures section of this earnings release.

2. Same-facility system-wide revenues and statistical information include the results of the facilities in which the Ambulatory segment has an investment that are not consolidated by Tenet. To help analyze the segment's results of operations, management uses system-wide measures, which include revenues and cases of both consolidated and unconsolidated facilities.

3. For 2025, same-hospital revenues and statistical data include those for hospitals and hospital-affiliated outpatient centers operated by the Company's Hospital segment continuously from January 1, 2024 through September 30, 2025. Amounts associated with physician practices are excluded.

4. Adjusted admissions represent actual patient admissions adjusted to include outpatient services provided by facilities in our Hospital segment by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues, then dividing that result by gross inpatient revenues.

5. Income tax expense is calculated by multiplying 24% (the federal corporate tax rate of 21% plus an estimate of state taxes) by the sum of: pretax income less GAAP facility level NCI expense plus permanent differences, and non-deductible interest expense.

6. Change versus prior year is presented on a same-facility system-wide basis for USPI Ambulatory surgical cases and on a same-hospital basis for hospital statistics.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates ambulatory surgery centers and surgical hospitals. We also operate a national portfolio of acute care and specialty hospitals, other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit https://www.tenethealth.com.

Contact Information

Investor Contact Media Contact

Will McDowell Robert Dyer

469-893-2387 469-893-2640

[e-mail] [e-mail]

Non-GAAP Financial Measures

The Company believes the non-GAAP measures described below are useful to investors and analysts because they present additional information on the Company's financial performance. Investors, analysts, Company management and the Company's Board of Directors utilize these non-GAAP measures, in addition to GAAP measures, to track the Company's financial and operating performance and compare the Company's performance to its peer companies, which use similar non-GAAP financial measures in their presentations and earnings releases. The Human Resources Committee of the Company's Board of Directors also uses certain of these measures to evaluate management's performance for the purpose of determining incentive compensation. Additional information regarding the purpose and utility of specific non-GAAP measures used in this release is set forth below.

• Adjusted EBITDA is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) the cumulative effect of changes in accounting principles, (2) net loss attributable (income available) to noncontrolling interests, (3) income (loss) from discontinued operations, net of tax, (4) income tax benefit (expense),

  (5) gain (loss) from early extinguishment of debt, (6) other non-operating income (expense), net, (7) interest expense,

  (8) litigation and investigation benefit (costs), net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition-related costs, (11) depreciation and amortization and (12) income (loss) from divested and closed businesses (i.e., health plan businesses). Litigation and investigation benefit (costs) excluded do not include ordinary course of business malpractice and other litigation and related expenses.

• Adjusted diluted earnings (loss) per share is defined by the Company as Adjusted net income available (loss attributable) to Tenet common shareholders, divided by the weighted average diluted shares outstanding in the reporting period.

• Adjusted net income available (loss attributable) to Tenet common shareholders is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) income (loss) from discontinued operations, net of tax, (2) gain (loss) from early extinguishment of debt, (3) litigation and investigation benefit (costs), net of insurance recoveries, (4) net gains (losses) on sales, consolidation and deconsolidation of facilities, (5) impairment and restructuring charges and acquisition-related costs, (6) income (loss) from divested and closed businesses (i.e., health plan businesses) and (7) the associated impact of these items on taxes and noncontrolling interests. Litigation and investigation benefit (costs) excluded do not include ordinary course of business malpractice and other litigation and related expenses.

• Free Cash Flow is defined by the Company as (1) net cash provided by (used in) operating activities, less (2) purchases of property and equipment.

• Adjusted Free Cash Flow is defined by the Company as (1) Adjusted net cash provided by (used in) operating activities, less (2) purchases of property and equipment.

• Adjusted net cash provided by (used in) operating activities is defined by the Company as cash provided by (used in) operating activities prior to (1) payments for restructuring charges, acquisition-related costs and litigation costs and settlements, and (2) net cash provided by (used in) operating activities from discontinued operations.

The Company believes that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to other GAAP and non-GAAP measures, as factors in determining the estimated fair value of shares of the Company's common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. The Company does not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance.

The Company uses, and believes investors use, Free Cash Flow and Adjusted Free Cash Flow as supplemental non-GAAP measures to analyze cash flows generated from the Company's operations. The Company believes these measures are useful to investors in evaluating its ability to fund distributions paid to noncontrolling interests or for acquisitions, purchasing equity interests in joint ventures or repaying debt.

These non-GAAP measures may not be comparable to similarly titled measures reported by other companies. Because these measures exclude many items that are included in the Company's financial statements, they do not provide a complete measure of the Company's operating performance. For example, the Company's definitions of Free Cash Flow and Adjusted Free Cash Flow do not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows from Financing Activities on the Company's Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, or (ii) distributions paid to noncontrolling interests. Accordingly, investors are encouraged to use GAAP measures when evaluating the Company's financial performance.

See corresponding reconciliations of the non-GAAP financial measures referred to above to the most comparable GAAP financial measures in Tables #1 - 6 below.